We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alnylam Pharmaceuticals

News List

Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock firstwordpharma
January 15, 2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 pharmafocusasia
November 28, 2018
Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment .......
Will more pharmas oppose Trump after Merck CEO's resignation? fiercepharma
August 16, 2017
Merck CEO Ken Frazier stepped down from President Donald Trump's manufacturing panel and getting a response from the president.

Previous page 1 2 Next page